EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

MOTIV Bioresorbable Scaffold in Below-The-Knee Artery Disease: European Post-Market Pilot BTK Trial: 36-Month Results

Michel J Bosiers, Thomas Rand, Raman Uberoi, Henrik Schroeder, Nasser Malyar, Dierk Scheinert, Andrej Schmidt

CardioVascular and Interventional Radiology · 2025

DOI: 10.1007/s00270-025-04202-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2025. Verfasst von Michel J Bosiers und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, St. Franziskus-Hospital, Münster, Germany. michel.bosiers@hotmail.com. Hauptthemen laut MEDLINE: Absorbable Implants, Peripheral Arterial Disease, Sirolimus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

THE primary objective of the MOTIV BTK PILOT STUDY WAs to evaluate the immediate and long-term safety and efficacy of the MOTIV® sirolimus-eluting bioresorbable scaffold (Reva Medical, San Diego, California, USA) in below-the-knee (BTK) arteries for the treatment of patients with rest pain or minor tissue loss (critical limb-threatening ischemia (CLTI)). Materials and Methods This is a prospective, single-arm, multi-center trial of a novel drug-eluting bioresorbable scaffold with a new scaffold material (Tyrocore®), which includes an iodinated, polycarbonate copolymer of tyrosine analogs and has a surface coating of the same Tyrocore material and the antiproliferative drug sirolimus. Fifty-eight patients were included between August 2019 and July 2021. The primary efficacy outcome measure was primary patency at 12 months. The primary safety outcome measure was freedom from serious device-related adverse events at 30 days. Secondary outcome measures were immediate technical success, primary patency at 24 and 36 months, clinically driven target lesion revascularization rate (CD-TLR) and limb salvage at 12, 24, and 36 months. Follow-up was performed at 1, 6, 24, and 36 months, including clinical assessment and core laboratory adjudicated color duplex ultrasound.

Results

Seventy-six MOTIV scaffolds were implanted in 60 study limbs with an average lesion length of 29.5 mm. Primary patency at 12, 24, and 36 months was 88.3%, 81.7%, and 80% (with numbers of limbs at risk being 43, 38 & 30) respectively. The 30-day adverse event rate was 1.7%. Technical success was achieved in 99%. At 3 years, freedom from CD-TLR was 93% and limb salvage rate was 95%.

Conclusion

The 36-month results of this pilot MOTIV BTK study demonstrated favorable safety and effectiveness performance in CLTI patients with BTK atherosclerotic disease. Level of Evidence: Level 3: non-randomized controlled cohort study. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Absorbable ImplantsPeripheral Arterial DiseaseSirolimusHumansFemalePilot ProjectsMaleProspective StudiesAgedMiddle AgedVascular PatencyProsthesis DesignLimb SalvageEuropeTreatment Outcome

Stichwörter der Autor:innen

BTKBioresorbable scaffoldsCLTIDrug-eluting technology

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Department of Vascular Surgery, St. Franziskus-Hospital, Münster, Germany. michel.bosiers@hotmail.com.
  • Department of Vascular Surgery, University Hospital Bern, University of Bern, Freiburgstrasse 18, 3010, Bern, Switzerland. michel.bosiers@hotmail.com.
  • Institute for Interventional and Diagnostic Radiology, Klinik Floridsdorf, Vienna, Austria.
  • Karl Landsteiner Institute for Interventional and Diagnostic Radiology, Vienna, Austria.
  • Department of Radiology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Institute for Interventional and Diagnostik Radiology at the Jewish Hospital Berlin, Berlin, Germany.

Förderung

  • University of Bern

Zitieren

APA

Bosiers, M. J., Rand, T., Uberoi, R., Schroeder, H., Malyar, N., Scheinert, D., & Schmidt, A. (2025). MOTIV Bioresorbable Scaffold in Below-The-Knee Artery Disease: European Post-Market Pilot BTK Trial: 36-Month Results. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-025-04202-8

Vancouver

Bosiers MJ, Rand T, Uberoi R, Schroeder H, Malyar N, Scheinert D, et al. MOTIV Bioresorbable Scaffold in Below-The-Knee Artery Disease: European Post-Market Pilot BTK Trial: 36-Month Results. CardioVascular and Interventional Radiology. 2025. doi:10.1007/s00270-025-04202-8

BibTeX
@article{Bosiers2025,
  author = {Bosiers, Michel J and Rand, Thomas and Uberoi, Raman and Schroeder, Henrik and Malyar, Nasser and Scheinert, Dierk and Schmidt, Andrej},
  title = {MOTIV Bioresorbable Scaffold in Below-The-Knee Artery Disease: European Post-Market Pilot BTK Trial: 36-Month Results},
  journal = {CardioVascular and Interventional Radiology},
  year = {2025},
  doi = {10.1007/s00270-025-04202-8}
}
Kostenlos starten →